180 Life Sciences Corp Stock Price, News & Analysis

180 Life Sciences Corp. (NASDAQ: ATNF) announced on July 12, 2021, that it regained compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2) after appointing new independent directors, thereby closing a compliance matter. The company had previously been notified of non-compliance by Nasdaq, which provided a 45-day period to submit a plan. After timely submission and an extension, the appointment of Pamela G. Marrone and Francis Knuettel II allowed the company to meet all requirements for continued listing.

180 Life Sciences Corp. (NASDAQ: ATNF) announced the publication of a review titled “Collagen VI as a driver and disease biomarker in human fibrosis” in the FEBS Journal. The study, authored by researchers from the University of Oxford, highlights the role of microfibrillar collagen VI in fibrotic diseases affecting vital organs. It identifies collagen VI cleavage fragments as potential biomarkers and therapeutic targets for fibrotic conditions. This publication underscores the company's commitment to advancing drug development for inflammatory diseases and fibrosis.

180 Life Sciences Corp. (NASDAQ: ATNF) announced its inclusion in the Russell Microcap® Index, effective June 28, 2021. This membership is expected to enhance the company’s visibility, increase stock liquidity, and broaden its shareholder base as the Russell indexes are widely used benchmarks for investment strategies.

CEO Dr. James Woody highlighted this inclusion as a pivotal validation for the company, aiming to propel long-term shareholder value. The Russell indexes are benchmarked by approximately $10.6 trillion in assets, indicating significant market relevance.

180 Life Sciences Corp. (ATNF) has been granted an extension until July 31, 2021, by Nasdaq to regain compliance with its listing rules after failing to file its 2020 Form 10-K and Q1 2021 Form 10-Q. The company initially received a notification regarding non-compliance on April 16, 2021, and submitted a compliance plan to Nasdaq by the June 15 deadline. The company is currently working to complete and file the overdue reports to maintain its listing on the Nasdaq.

180 Life Sciences Corp. (NASDAQ: ATNF) has appointed Pamela Marrone, PhD, and Frank Knuettel II, MBA, to its Board of Directors, effective upon the earlier of the filing of the 2020 Form 10-K or June 28, 2021. Dr. Marrone brings over 30 years of experience in biotech, including notable success with Marrone Bio Innovations, with a 5-year revenue CAGR of ~30%. Knuettel has over 25 years in management and finance, previously serving in significant roles within cannabis companies. CEO James Woody expressed confidence that their distinct skill sets will enhance shareholder value.

180 Life Sciences Corp. (ATNF) announced management's presentation at the LD Micro Invitational XI, set for June 10, 2021, at 1:30 p.m. EDT. The virtual event will allow investors to hear insights from CEO Dr. James Woody. The conference runs from June 8-10, 2021, and a live audio webcast will be available. 180 Life Sciences focuses on developing innovative drugs for inflammatory diseases, fibrosis, and pain, collaborating with experts from prestigious institutions like Oxford and Stanford.

180 Life Sciences Corp. (NASDAQ: ATNF) announced the appointment of Russell T. Ray and Teresa DeLuca, MD, MBA, to its Board of Directors, effective June 15, 2021. Russell Ray has extensive experience in corporate finance within the healthcare sector, previously serving at Credit Suisse and as a venture partner. Teresa DeLuca brings over 20 years of healthcare management expertise, including roles at Fortune 50 companies and Columbia University. The additions aim to enhance board governance and satisfy Nasdaq’s independent director requirements, thereby potentially increasing shareholder value.

180 Life Sciences Corp. (NASDAQ: ATNF) has successfully collected and submitted all patient data from its Phase 2b clinical trial for Dupuytren’s disease, conducted in partnership with the University of Oxford. The trial involved 181 patients and analyzed the efficacy of adalimumab, administered over a series of injections. Despite delays due to the COVID-19 pandemic, data analysis is underway, with results expected to be released in Q4 2021. This trial addresses a significant medical need, as no current approved therapies exist for early-stage Dupuytren’s disease, potentially impacting patient quality of life.

180 Life Sciences Corp. (NASDAQ: ATNF) announced that it received a notification from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the pending filing of its 2020 Form 10-K. The letter does not immediately impact trading on Nasdaq. The company is currently addressing delays in financial statements following amended filings for its predecessor and a recent SEC statement on warrants. 180 Life Sciences has until June 15, 2021, to file the 10-K and may seek a plan to regain compliance if delayed further, risking potential delisting.